StormBio, Inc. is a development stage, privately held, biopharmaceutical company, focused on the development of therapeutics for treating Highly Pathogenic Influenza. StormBio's treatments will be effective against a variety of influenza strains, including the currently evolving Type A H1N1 (swine) flu, H5N1 (avian flu), and deadly cases of H3N2 (seasonal) flu. Our therapeutics are also expected to be useful in treating other acute inflammatory diseases.
The company is currently creating a therapeutic murine model for Highly Pathogenic Influenza and is evaluating therapeutic candidates that regulate hypercytokinemia, or cytokine storm, (without disabling the immune system).
Much of our animal-model research testing was conducted at National Heart and Lung Institute, Imperial College, London.